Concordance and discordance in SLE clinical trial outcome measures: analysis of 3 anifrolumab phase 2/3 trials Watch our video abstract: https://t.co/l1JNsHGl8m
Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
Mentions
Extended reach
Total likes
Video views
Mentions per month
Jun 2022All 3 dated mentions so far are from Jun 2022.
Where it's discussed
-
X / Twitter2 posts
-
News2 articles
-
YouTube1 videos
AI synopsis
What people are saying
The discussions mainly revolve around promoting the article through phrases like 'Watch our video,' indicating moderate engagement and interest. The tone is neutral and informational, with little critical analysis or debate, which leads to balanced scores across agreement and impact.
Most discussions simply reference the article, showing neutral feelings with neither strong agreement nor disagreement.
Moderate interest is indicated by the calls to watch the video abstract, suggesting curiosity but limited deeper engagement.
Posts are mostly surface-level, sharing the publication link or video without detailed analysis.
The discussions acknowledge the importance of the study, but they do not indicate widespread influence or controversy within the community.
Top posts
Most liked on X and BlueskyRT @ARD_BMJ: Concordance and discordance in SLE clinical trial outcome measures: analysis of 3 anifrolumab phase 2/3 trials Watch our video…
All mentions
Analyzing Concordance in SLE Clinical Trial Outcomes with Anifrolumab
This video explores the concordance and discordance in systemic lupus erythematosus SLE trial outcomes from three phases of anifrolumab studies, focusing on factors influencing trial results and treatment responses.
RT @ARD_BMJ: Concordance and discordance in SLE clinical trial outcome measures: analysis of 3 anifrolumab phase 2/3 trials Watch our video…
Concordance and discordance in SLE clinical trial outcome measures: analysis of 3 anifrolumab phase 2/3 trials Watch our video abstract: https://t.co/l1JNsHGl8m